The US FDA has approved Ionis-AstraZeneca to treat rare nerve diseases. The US Food and Drug Administration approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat rare nerve diseases on Thursday.
This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am
The planned FDA submission follows the report from AstraZeneca and Ionis Pharmaceuticals that their partnered drug, eplontersen, met the main goals of a pivotal study in treating nerve pain caused by hereditary transthyretin-mediated amyloidosis. The data come one week after rival Alnylam Pharmaceuticals won FDA approval for its second drug for this rare disease.